(Q33391844)

English

Temsirolimus: In relapsed and/or refractory mantle cell lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Temsirolimus: In relapsed and/or refractory mantle cell lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

mantle cell lymphoma

1 reference

based on heuristic

inferred from title

2

object named as

Kate McKeage

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Sheridan M Hoy

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1819-1829

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus: in advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic options in mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current management of mantle cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20836575

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11204940-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33391844&oldid=2195315537"